Sustained pro-haemostatic activity of rFVIIa in plasma and platelets in non-bleeding pigs may explain the efficacy of a once-daily prophylaxis in humans

Thrombosis and Haemostasis

Volumn 112, Issue 2, 2014, Pages 304-310

  Schut, Anne Marieke ^a   Hyseni, Agon ^b   Adelmeijer, Jelle ^a   Meijers, Joost C M ^c   de Groot, Philip G ^b   Lisman, Ton ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Factor VIIa; Haemophilia; Platelet; Prophylaxis; Thrombin generation

Indexed keywords

ACTIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A; COAGULATING AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN; THROMBIN;

ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CELL LYSATE; DRUG EFFICACY; FIBRINOLYSIS; HEMOPHILIA; HEMOSTASIS; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE DRUG DOSE; THROMBOCYTE; TURBIDITY; ANIMAL; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; HUMAN; INJECTION; METABOLISM; PIG;

ANIMALS; BLOOD PLATELETS; COAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FACTOR VIIA; HEMOSTASIS; HUMANS; INJECTIONS; PROTHROMBIN TIME; RECOMBINANT PROTEINS; SWINE; THROMBIN;

EID: 84905181929     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-09-0798     Document Type: Article

References (26)

1. Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) Registry. Blood 2012; 120: 39-46.
2. Lusher JM, Roberts HR, Davignon G, et al. A randomized, double-blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. rFVIIa Study Group. Haemophilia 1998; 4: 790-798.
3. Salaj P, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HaemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-759.
4. Sørensen B, Dargaud Y, Kenet G, et al. On-demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII. Haemophilia 2012; 18: 255-262.
5. Young G, Cooper DL, Gut RZ, et al. Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008). Haemophilia 2012; 18: 990-996.
6. Lisman T, De Groot PG. Mechanism of action of recombinant factor VIIa. J. Thromb. Haemost. 2003; 1: 1138-1139.
7. Lisman T, Adelmeijer J, Cauwenberghs S, et al. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count. J Thromb Haemost 2005; 3: 742-751.
8. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood 2002; 99: 175-179.
9. Young G, Auerswald G, Jimenez-Yuste V, et al. When should prophylaxis therapy in inhibitor patients be considered? Haemophilia 2011; 17: e849-857.
10. Teitel JM, Sholzberg M. Current status and future prospects for the prophylactic management of haemophilia patients with inhibitor antibodies. Blood Rev 2013; 27: 103-109.
11. Konkle BA, Ebbesen LS, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in haemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-1913.
12. Young G, Auerswald G, Jimenez-Yuste V, et al. PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in haemophilia patients with inhibitors. Thromb Res 2012; 130: 864-870.
13. Mathijssen NC, Masereeuw R, Verbeek K, et al. Prophylactic effect of recombinant factor VIIa in factor VII deficient patients. Br J Haematol 2004; 125: 494-499.
14. Mariani G, Dolce A, Napolitano M, et al. Invasive procedures and minor surgery in factor VII deficiency. Haemophilia 2012; 18: e63-65.
15. Gopalakrishnan R, Hedner U, Clark C, et al. rFVIIa transported from the blood stream into tissues is functionally active. J Thromb Haemost 2010; 8: 2318-2321.
16. Gopalakrishnan R, Hedner U, Ghosh S, et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost 2010; 8: 301-310.
17. Lopez-Vilchez I, Tusell J, Hedner U, et al. Traffic of rFVIIa through endothelial cells and redistribution into subendothelium: implications for a prolonged haemostatic effect. J Coag Disorders 2009; 1: 1-6.
18. Beeby TL, Chasseaud LF, Taylor T, et al. Distribution of the recombinant coagulation factor 125I-rFVIIa in rats. Thromb Haemost 1993; 70: 465-468.
19. Lopez-Vilchez I, Hedner U, Altisent C, et al. Redistribution and haemostatic action of recombinant activated factor VII associated with platelets. Am J Pathol 2011; 178: 2938-2948.
20. Peterson JE, Zurakowski D, Italiano JE, Jr, et al. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010; 85: 487-493.
21. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002; 106: 2550-2554.
22. Friederich PW, Levi M, Bauer KA, et al. Ability of recombinant factor VIIa to generate thrombin during inhibition of tissue factor in human subjects. Circulation 2001; 103: 2555-2559.
23. Villar A, Aronis S, Morfini M, et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-359.
24. Lindley CM, Sawyer WT, Macik BG, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-648.
25. Levi M, Peters M, Büller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890.
26. Tiede A, Friedrich U, Stenmo C, et al. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa). J Thromb Haemost 2011; 9: 1191-1199.